These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33503832)

  • 1. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
    Pham TND; Shields MA; Spaulding C; Principe DR; Li B; Underwood PW; Trevino JG; Bentrem DJ; Munshi HG
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma.
    Holokai L; Chakrabarti J; Lundy J; Croagh D; Adhikary P; Richards SS; Woodson C; Steele N; Kuester R; Scott A; Khreiss M; Frankel T; Merchant J; Jenkins BJ; Wang J; Shroff RT; Ahmad SA; Zavros Y
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348809
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.
    Suri R; Zimmerman JW; Burkhart RA
    Ann Pancreat Cancer; 2020 Dec; 3():. PubMed ID: 33889840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.
    Zhang J; Wolfgang CL; Zheng L
    Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29385739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical models of pancreatic ductal adenocarcinoma.
    Krempley BD; Yu KH
    Chin Clin Oncol; 2017 Jun; 6(3):25. PubMed ID: 28705002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.
    Garcia PL; Miller AL; Yoon KJ
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
    Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
    World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives.
    Stoof J; Harrold E; Mariottino S; Lowery MA; Walsh N
    Front Cell Dev Biol; 2021; 9():749490. PubMed ID: 34712667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
    Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
    Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer.
    Macherla S; Laks S; Naqash AR; Bulumulle A; Zervos E; Muzaffar M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impacting Pancreatic Cancer Therapy in Heterotypic
    Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
    Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
    Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
    J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.